Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 4, Issue 3, Pages 255-271Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557043487394
Keywords
FLT3; tyrosine kinase; kinase inhibitor; AML; KIT; PDGFR
Categories
Ask authors/readers for more resources
Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
